Breaking News, Collaborations & Alliances

DNAtrix, Valo Therapeutics Enter Strategic R&D Pact

To combine DNAtrix's oncolytic adenovirus platform and Valo's PeptiCRAd vaccination technology for "armed oncolytic vaccine"

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

DNAtrix and Valo Therapeutics entered an exclusive R&D collaboration to develop enhanced vaccines using DNAtrix’s clinical stage viruses and Valo’s antigenic peptide technology.  DNAtrix’s clinical stage oncolytic adenovirus platform and Valo’s PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) vaccination technology will be combined to generate a novel “armed oncolytic vaccine” for cancer therapy.  While oncolytic adenoviruses alone offer ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters